Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the exception of oxycodone, little information exists regarding the impact of abuse deterrent products on reducing abuse/misuse of opioid products.Studies have shown that Medicaid patients are dispensed opioids at a higher rate, abuse opioids at a higher rate, and experience more morbidity and mortality than other populations. In this study we seek to quantify misuse, abuse, dependence, and health resource use in a Medicaid patient sample prescribed an abuse deterrent formulation of extended release morphine (EMBEDA®) or non-abuse deterrent extended release morphine (ERM).

Explore related content and topics